Clinical trials: Metastatic Squamous Cell Carcinoma Neck
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Head and Neck Squamous Cell Carcinoma
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous…
- Trial name
- NCT06308913
- Testing
- INCB081776, Pembrolizumab, Palliative RT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
- Trial name
- NCT00021424
- Testing
- recombinant fowlpox-TRICOM vaccine
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Cancer, Human Papilloma Virus
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination…
- Trial name
- NCT03162224
- Testing
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma, Circulating Tumor Cell
PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT
Head and neck squamous cell carcinoma (HNSCC) is the 4th highest incidence of cancer and 6th of cancer death of the males in Taiwan.
- Trial name
- NCT05008796
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Esophageal Squamous Cell Carcinoma
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable…
- Trial name
- NCT06022861
- Testing
- LY01015, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Carcinoma, Squamous Cell of Head and Neck
Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients
The purpose of this study is to identify predictive and pharmacodynamic biomarkers of activity and efficacy of pre-operative Afatinib (BIBW2992) in untreated non-metastatic head and neck squamous cell carcinoma patients
- Trial name
- PREDICTOR (NCT01415674)
- Testing
- Afatinib
- Where
- 11 sites in France
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Squamous Cell Carcinoma
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients…
- Trial name
- NCT07435324
- Testing
- RPH-002, Erbitux®, Cisplatin
- Where
- 34 sites in Russia, Uzbekistan
- Volunteers
- 161 people
- Sponsor
- R-Pharm
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has…
- Trial name
- NCT03868020
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
This study is a prospective,open-label,single-arm clinical trial to evaluate the efficacy and safety of s Surufatinib combined with envolizumab as second-line treatment of recurrent/metastatic head and neck squamous cell…
- Trial name
- HNSCC (NCT06876844)
- Testing
- combination of Surufatinib and Envolizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to…
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06211335
- Testing
- Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
Head and Neck Cancer
Capecitabine For Nasopharyngeal Cancer
This study plans to examine the effects of Capecitabine administered as an oral chemotherapy drug in participants with nasopharyngeal cancer. Capecitabine is an oral prodrug.
- Trial name
- NCT00095901
- Testing
- Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of the Head and Neck
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic…
- Trial name
- CHANGE (NCT01177956)
- Testing
- Cetuximab, Cisplatin, 5-Fluorouracil
- Where
- 14 sites in China, South Korea
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT01637194
- Testing
- everolimus, cetuximab, pharmacological study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.